Assessment of clinician adherence to Fingolimod instructions and its effect on patient safety

References

1. 1.↵
   NICE guideline [NG220]. 2022. 2022. Multiple sclerosis in adults: management. https://www.nice.org.uk/guidance/ng220
2. 2.↵
   1. AlJumah M,
   2. Bunyan R,
   3. Al Otaibi H,
   4. Al Towaijri G,
   5. Karim A,
   6. Al Malik Y, et al.

   Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study. BMC Neurol 2020; 20: 49.

   OpenUrl
3. 3.↵
   1. Montalban X,
   2. Gold R,
   3. Thompson AJ,
   4. Otero-Romero S,
   5. Amato MP,
   6. Chandraratna D, et al.

   ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur J Neurol 2018; 25: 215-237.

   OpenUrlCrossRefPubMed
4. 4.↵
   National Clinical Guideline Centre (UK). Multiple Sclerosis: Management of Multiple Sclerosis in Primary and Secondary Care. London (UK): National Institute for Health and Care Excellence (UK); 2014.
5. 5.↵
   1. Saguil A,
   2. Kane S,
   3. Farnell E.

   Multiple sclerosis: a primary care perspective. Am Fam Physician 2014; 90: 644-652.

   OpenUrl
6. 6.↵
   1. Tramacere I,
   2. Del Giovane C,
   3. Salanti G,
   4. D’Amico R,
   5. Filippini G.

   Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2015; 2015: CD011381.
7. 7.↵
   1. Rae-Grant A,
   2. Day GS,
   3. Marrie RA,
   4. Rabinstein A,
   5. Cree BAC,
   6. Gronseth GS, et al.

   Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90: 777-788.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Kappos L,
   2. Radue EW,
   3. O’Connor P,
   4. Polman C,
   5. Hohlfeld R,
   6. Calabresi P, et al.

   A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Cohen JA,
   2. Barkhof F,
   3. Comi G,
   4. Hartung HP,
   5. Khatri BO,
   6. Montalban X, et al.

   Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-415.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    ©Novartis. MEDICATION GUIDE GILENYA^® (je-LEN-yah) (fingolimod) capsules. https://www.novartis.com/sg-en/sites/novartis_sg/files/Gilenya-Dec2020.SIN-app220321.pdf.
11. 11.
    1. Gajofatto A,
    2. Turatti M,
    3. Monaco S,
    4. Benedetti MD.

    Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. Drug Healthc Patient Saf 2015; 7: 157-167.

    OpenUrl
12. 12.↵
    1. Arvin AM,
    2. Wolinsky JS,
    3. Kappos L,
    4. Morris MI,
    5. Reder AT,
    6. Tornatore C, et al.

    Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 2015; 72: 31-39.

    OpenUrl
13. 13.↵
    1. Brown B,
    2. Weiss JL,
    3. Kolodny S,
    4. Meng X,
    5. Williams IM,
    6. Osborne JA.

    Analysis of cardiac monitoring and safety data in patients initiating fingolimod treatment in the home or in clinic. BMC Neurol 2019; 19: 287.

    OpenUrl
14. 14.↵
    1. Kennedy PJ,
    2. Leathley CM,
    3. Hughes CF.

    Clinical practice variation. Med J Aust 2010; 193: S97-D99.

    OpenUrlPubMedWeb of Science
15. 15.↵
    1. Adedeji AR,
    2. Tumbo J,
    3. Govender I.

    Adherence of doctors to a clinical guideline for hypertension in Bojanala district, North-West Province, South Africa. Afr J Prim Health Care Fam Med 2015; 7: 776.

    OpenUrl
16. 16.↵
    1. Abdelgadir HS,
    2. Elfadul MM,
    3. Hamid NH,
    4. Noma M.

    Adherence of doctors to hypertension clinical guidelines in academy charity teaching hospital, Khartoum, Sudan. BMC Health Serv Res 2019; 19: 309.

    OpenUrl
17. 17.↵
    1. Dhanaraj E,
    2. Raval A,
    3. Yadav R,
    4. Bhansali A,
    5. Tiwari P.

    Prescription Pattern of Antihypertensive Agents in T2DM Patients Visiting Tertiary Care Centre in North India. Int J Hypertens 2012; 2012: 520915.

    OpenUrl
18. 18.↵
    1. Agashivala N,
    2. Wu N,
    3. Abouzaid S,
    4. Wu Y,
    5. Kim E,
    6. Boulanger L, et al.

    Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. BMC Neurol 2013; 13: 138.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Zimmer A,
    2. Coslovsky M,
    3. Abraham I,
    4. Décard BF.

    Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study. Patient Prefer Adherence 2017; 11: 1815-1830.

    OpenUrl